Why is Boston Scientific Corporation stock rising?
Penumbra acquisition expected to close in second-half 2026, adding neurovascular and pulmonary embolism portfolios.
Entry into the coronary IVL market with SEISMIQ 4CE planned for 2027.
FARAWAVE Ultra launch and ICE market entry expected to improve U.S. EP performance in second-half 2027.
Option to acquire MiRus TAVR assets creates a path to reenter the TAVR market.
FARADIGM pivotal enrollment started for FARAFLEX mapping and PFA catheter, supporting a 2028 launch.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Boston Scientific Corporation and 4,900+ companies.